Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting weight ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.

Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

Bullish option flow detected in Viking Therapeutics (VKTX) with 8,905 calls trading, 2x expected, and implied vol increasing over 15 points to ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for ...

Viking has found a manufacturing partner, removing a key overhang on the stock Viking Therapeutics Inc.'s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a ...